4D Molecular Therapeutics (NASDAQ:FDMT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of 4D Molecular Therapeutics (NASDAQ:FDMT) from a sell rating to a hold rating in a research report released on Saturday morning.

Several other brokerages also recently issued reports on FDMT. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 21st. Barclays assumed coverage on 4D Molecular Therapeutics in a research note on Wednesday, January 28th. They set an “overweight” rating and a $33.00 target price on the stock. Royal Bank Of Canada lifted their price target on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a report on Thursday, March 19th. HC Wainwright restated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, 4D Molecular Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $32.71.

4D Molecular Therapeutics Price Performance

Shares of FDMT opened at $9.23 on Friday. The firm has a market capitalization of $471.19 million, a PE ratio of -3.81 and a beta of 2.99. The company’s 50-day moving average is $8.79 and its 200-day moving average is $9.16. 4D Molecular Therapeutics has a fifty-two week low of $2.23 and a fifty-two week high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Wednesday, March 18th. The company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.96. The company had revenue of $85.09 million during the quarter, compared to analysts’ expectations of $30.86 million. 4D Molecular Therapeutics had a negative net margin of 164.43% and a negative return on equity of 31.75%. Analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wexford Capital LP bought a new stake in shares of 4D Molecular Therapeutics in the third quarter valued at approximately $41,000. Farther Finance Advisors LLC increased its stake in 4D Molecular Therapeutics by 117.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after acquiring an additional 2,674 shares during the period. Daiwa Securities Group Inc. raised its holdings in 4D Molecular Therapeutics by 3,362.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after acquiring an additional 6,186 shares in the last quarter. Abich Financial Wealth Management LLC acquired a new position in 4D Molecular Therapeutics in the 3rd quarter valued at $80,000. Finally, Susquehanna Portfolio Strategies LLC bought a new stake in shares of 4D Molecular Therapeutics during the 4th quarter valued at $77,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.